Affimed N.V. reports promising results from AFM24-102 trial in NSCLC
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study, showcasing significant advances in treating non-small cell lung cancer (NSCLC). This data, involving both EGFR wild-type (EGFRwt) and mutated (EGFRmut) NSCLC cohorts, marks a pivotal step in leveraging the innate immune system to combat cancer effectively. Clinical […]